Gland Pharma Ltd. · NSE:GLAND
Gland Pharma — Q3 FY25 Earnings Presentation
16 slides from Gland Pharma's earnings presentation, Feb 3, 2025
Slide 1: Investor Presentation Q3 & 9M FY25
GLAND PHARMA Investor Presentation Q3 & 9M FY25 03 February 2025
Slide 2: Safe Harbour Statement
Safe Harbour Statement The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendatio
Slide 3: Consolidated P&L Highlights
Consolidated P&L Highlights ₹ Mn Particulars Q3 FY25 Q3 FY24 YoY Q2 FY25 QoQ 9M FY25 9M FY24 YoY Revenue from operations 13,841 15,452 -10% 14,058 -2% 41,916 41,273 2% Other Income 585 374 56% 596 -2% 1,696 1,281 32% Total Income 14,426 15,826 -9% 14,654 -2% 43,612 42,554 2% Gross Profit (1) 9,213 9
Slide 4: Consolidated Financial Highlights
Consolidated Financial Highlights Revenue from Operations Gross Profit (1) / Gross Profit Margin (2) (₹ Mn) (₹ Mn / %) 1% 2% 25,536 25,892 41,273 41,916 62% 62% 15,452 9,459 8,304 9,213 14,058 13,841 61% 67% 59% Q3 FY24 Q2 FY25 Q3 FY25 9M FY24 9M FY25 Q3 FY24 Q2 FY25 Q3 FY25 9M FY24 9M FY25 EBITDA (
Slide 5: Base Business (Gland) Financial Highlights (1/2)
Base Business (Gland) Financial Highlights (1/2) Revenue from Operations EBITDA Margin (1) / PAT / PAT Margin (2) (₹ Mn) (₹ Mn / %) 33% 34% 30,032 30,917 7,955 7,296 26% -8% 34% 34% 39% 24% 11,013 10,659 10,123 2,808 2,843 2,864 25% 27% 28% Q3 FY24 Q2 FY25 Q3 FY25 9M FY24 9M FY25 Q3 FY24 Q2 FY25 Q3
Slide 6: Base Business (Gland) Financial Highlights (2/2)
Base Business (Gland) Financial Highlights (2/2) ₹ Mn Particulars Q3 FY25 Q3 FY24 YoY Q2 FY25 QoQ 9M FY25 9M FY24 YoY Revenue from operations 10,123 11,013 -8% 10,659 -5% 30,917 30,032 3% Gross Profit 6,357 6,128 4% 5,957 7% 17,663 16,996 4% % margin 63% 56% 56% 57% 57% EBITDA 3,911 3,727 5% 3,645 7
Slide 7: Cenexi Performance
Cenexi Performance Q3 FY25 Q3 FY24 Q2 FY25 9M FY25 9M FY24* Particulars YoY QoQ YoY € Mn. ₹ Mn. € Mn. ₹ Mn. € Mn. ₹ Mn. € Mn. ₹ Mn. € Mn. ₹ Mn. Revenue from 41 3,717 50 4,439 -16% 37 3,399 9% 121 10,999 125 11,240 -2% operations Gross Profit 32 2,856 37 3,331 -14% 25 2,347 22% 91 8,229 95 8,540 -4%
Slide 8: Geographical Revenue Mix
SS Geographical — Revenue Mix
Slide 9: US Market
US Market ₹ Mn Group Revenue Contribution Gland Cenexi 4% YoY 5% YoY -23% YoY -11% YoY -12% YoY 5% YoY 21,591 22,469 21,053 22,052 538 417 8,216 7,547 7,293 8,065 7,393 7,135 151 154 158 Q3 FY24 Q2 FY25 Q3 FY25 9M FY24 9M FY25 Q3 FY24 Q2 FY25 Q3 FY25 9M FY24 9M FY25 Q3 FY24 Q2 FY25 Q3 FY25 9M FY24 9
Slide 10: Europe Market
Europe Market ₹ Mn Group Revenue Contribution Gland Cenexi -19% YoY -4% YoY 30% YoY 7% YoY -5% YoY -24% YoY 1,079 1,155 7,963 7,672 6,884 6,517 3,251 2,646 329 419 2,928 2,227 2,459 323 2,130 Q3 FY24 Q2 FY25 Q3 FY25 9M FY24 9M FY25 Q3 FY24 Q2 FY25 Q3 FY25 9M FY24 9M FY25 Q3 FY24 Q2 FY25 Q3 FY25 9M F
Slide 11: Other Core Markets (Canada, Australia and New Zealand)
Other Core Markets (Canada, Australia and New Zealand) ₹ Mn Group Revenue Contribution Gland Cenexi 20% YoY 42% YoY 37% YoY 16% YoY 34% YoY 53% YoY 937 1,420 683 483 998 405 338 315 514 459 292 382 121 90 109 Q3 FY24 Q2 FY25 Q3 FY25 9M FY24 9M FY25 Q3 FY24 Q2 FY25 Q3 FY25 9M FY24 9M FY25 Q3 FY24 Q2
Slide 12: Rest of the World
Rest of the World ₹ Mn Group Revenue Contribution Gland Cenexi 1% YoY -1% YoY 6% YoY -3% YoY -5% YoY 2% YoY 4,934 4,810 8,437 8,392 3,503 3,582 2,842 2,663 2,881 1,573 1,658 1,669 1,269 1,005 1,212 Q3 FY24 Q2 FY25 Q3 FY25 9M FY24 9M FY25 Q3 FY24 Q2 FY25 Q3 FY25 9M FY24 9M FY25 Q3 FY24 Q2 FY25 Q3 FY2
Slide 13: India
India ₹ Mn Gland India Contribution to the Group Business Update -26% YoY -14% YoY 4% Revenue declined due to a decrease in 2,283 volume 1,963 9MFY25 761 874 562 Q3 FY24 Q2 FY25 Q3 FY25 9M FY24 9M FY25 13
Slide 14: Group Financial Highlights (1/2)
Group Financial Highlights (1/2) Net Worth (1) ROCE (2) / RONW (3) (₹ Mn) (%) RoCE RoNW 87,238 88,994 79,587 11% 11% 9% 11% 9% 8% FY23 FY24 9M FY25 FY23 FY24 9M FY25 Capital Expenditure Asset Turnover Ratio (4)(5) (₹ Mn) (x) 3,975 3,053 2.2 2,230 1.5 1.5 0.5 0.6 0.5 FY23 FY24 9M FY25 Total asset tur
Slide 15: Group Financial Highlights (2/2)
Group Financial Highlights (2/2) Cash and Bank Balances / Net Cash (1) Cash Flow from Operations (₹ Mn) Total Cash (₹ Mn) Net Cash 9,968 37,707 37,669 27,189 5,889 24,953 24,122 21,756 3,640 FY23 FY24 9M FY25 FY23 FY24 9M FY25 Net Working Capital (2) Cash Conversion Cycle (CCC) (3)(4) (₹ Mn) (# of D
Slide 16: Thank You
GLAND PHARMA Thank You Investor Relations: Corporate Office Gland Pharma Gland Pharma Limited Sampath Kumar Pallerlamudi Plot No. 11 & 84, TSIIC Phase: IV Company Secretary & Compliance Officer Pashamylaram (V), Patancheru (M), Sangareddy District EY Investor Relations Hyderabad 502307, Telangana, I